Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05089760
Other study ID # MAROC-ChiNICU
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date December 31, 2024

Study information

Verified date August 2023
Source Children's Hospital of Fudan University
Contact Yun Cao, Ph.D. M.D.
Phone +8602164931160
Email yuncao@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Neonatal sepsis remains one of the most important cause of mortality and morbidities in China. This study will establish a prospective registral cohort of all infants with culture-proven neonatal sepsis in Chinese NICUs participating in the Chinese Neonatal Network (CHNN). The microbiology, antimicrobial resistance patterns and neonatal outcomes will be described in detail for this cohort.


Description:

All infants with culture-proven sepsis in NICUs of CHNN will be enrolled in the study. Detailed data on microbiology, resistance pattern, neonatal mortality and morbidities will be collected and described. Risk factors for multi-resistant bacteria infections and for sepsis-related mortality will be identified.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1200
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Hour to 1 Month
Eligibility Inclusion Criteria: - Admitted to CHNN NICUs from 2022.1.1 to 2023.12.31 - Diagnosed with culture-proven sepsis Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospital of Fudan University Chinese Neonatal Network

Outcome

Type Measure Description Time frame Safety issue
Primary Overall mortality Incidence of death during the study period About 3 months from admission to discharge or death
Secondary Sepsis-related mortality (within 7 days of sepsis) Incidence of death within 7 days after sepsis About 3 months from admission to discharge or death
Secondary Incidence of multiorgan dysfunction Propertion of infants who occur multiorgan dysfunction About 3 months from admission to discharge or death
Secondary Incidence of septic shock Propertion of infants who occur septic shock About 3 months from admission to discharge or death
Secondary Incidence of respiratory failure Propertion of infants who occur respiratory failure About 3 months from admission to discharge or death
Secondary Incidence of disseminated intravascular coagulation (DIC) Propertion of infants who occur DIC About 3 months from admission to discharge or death
Secondary Incidence of renal failure Propertion of infants who accur renal failure About 3 months from admission to discharge or death
Secondary Incidence of meningitis Propertion of infants who accur meningitis About 3 months from admission to discharge or death
Secondary Incidence of necrotizing enterocolitis Propertion of infants who accur necrotizing enterocolitis About 3 months from admission to discharge or death
Secondary Incidence of brain injury Propertion of infants who accur brain injury About 3 months from admission to discharge or death
Secondary Length of hospital stay Days of hospitalization About 3 months from admission to discharge or death
Secondary Length of antibiotic treatment Days of antibiotic treatment About 3 months from admission to discharge or death
Secondary Type and quantity of transfusion Which kind and how much (ml) of blood product was used during the study About 3 months from admission to discharge or death
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05692128 - Frequency and Severity of Thrombocytopenia in Neonatal Sepsis
Completed NCT00942084 - A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) Phase 1
Completed NCT06002295 - A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns Phase 2
Not yet recruiting NCT05114057 - Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI N/A
Recruiting NCT04528251 - Comparison of the Effectiveness of Two Different Antibiotic Regimens of the Treatment of Pregnant Women With Preterm Rupture of Membranes
Active, not recruiting NCT03871491 - Azithromycin-Prevention in Labor Use Study (A-PLUS) Phase 3
Completed NCT03746743 - Severity Index of Neonatal Septicemia Using Score for Neonatal Acute Physiology (SNAP) II
Completed NCT02386592 - Prevention of Nosocomial Bacteremia Among Zambian Neonates N/A
Not yet recruiting NCT06113653 - Outcomes and Predictors of Mortality Among Preterm Infants With Neonatal Sepsis
Completed NCT03199547 - Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death Phase 3
Completed NCT02147327 - Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities N/A
Completed NCT01005589 - CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis N/A
Completed NCT00866567 - Defects in Opsonophagocytosis in Premature Infants N/A
Completed NCT02281890 - Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database N/A
Suspended NCT05156333 - Probiotics and GBS Colonization in Pregnancy N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Completed NCT03755635 - Neonatal Sepsis at Neonatal Intensive Care Units in Ghana N/A
Completed NCT03247920 - Reduction of Intravenous Antibiotics In Neonates Phase 4
Completed NCT03295162 - Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis Phase 1/Phase 2
Completed NCT02954926 - Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis Phase 3